{"classes":[{"categories":[{"measurements":[{"comment":"75th percentile value not calculable due to insufficient data.","groupId":"OG000","lowerLimit":"11.2","upperLimit":"NA","value":"22.1"},{"groupId":"OG001","lowerLimit":"11.3","upperLimit":"30.4","value":"19.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"description":"DoCB was defined only for patients who had clinical benefit, as the time in days from date of randomisation until the date of disease progression.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Patients received fulvestrant (Faslodex™) 500 mg, administered as two 5 mL intramuscular injections, 1 in each buttock, at each visit on Days 0, 14 (±3), 28 (±3) and every 28 (±3) days thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive fulvestrant, also received placebo to match the anastrozole schedule (tablets, once daily).","id":"OG000","title":"Fulvestrant 500 mg"},{"description":"Patients received anastrozole (Arimidex™), administered orally as a single tablet at a dose of 1 mg/day from randomisation on Day 0 and once daily thereafter. In order to support the double-blind, double-dummy design of the trial, each patient randomised to receive anastrozole also received placebo to match the fulvestrant schedule (injections on Days 0, 14 \\[±3\\], 28 \\[±3\\] and every 28 \\[±3\\] days thereafter).","id":"OG001","title":"Anastrozole 1 mg"}],"paramType":"MEDIAN","populationDescription":"Only patients in the ITT analysis set (which included all randomised patients) who also had a clinical benefit were included in the DoCB analysis (n=180 for Fulvestrant arm and n=172 for Anastrozole arm).","reportingStatus":"POSTED","timeFrame":"Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)","title":"Duration of Clinical Benefit (DoCB) for Fulvestrant Treatment Versus Anastrozole Treatment","type":"SECONDARY","unitOfMeasure":"Months"}